Last updated: 2026-09-16 12:10:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Spruce Biosciences, Inc. (SPRB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $55.52, with a market capitalisation of $163.39M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.26 to $240.00. This page covers its latest market performance, valuation, price trends and company information.
$163.39M | |
$55.52 | |
$2,670.00 | |
$4.28 | |
$55.17 | |
7.00 | |
79.35K | |
-- | |
$240.00 | |
$7.26 | |
-- | |
-- |
Spruce Biosciences, Inc. (SPRB) is trading at $55.52 in pre-market trading as of 2026-09-16 11:15:00, up 0.64% ($0.36) from the previous close of $55.17
Pre-market trading shows how investors are pricing SPRB before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Spruce Biosciences, Inc. (SPRB) moved from $57.93 to $55.52, representing a decline of 4.16% ($2.41).
The stock traded between $52.66 and $60.51 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 116.34 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 20.7%
SPRB is currently trading at $55.52, placing it 20.7% of the way from its 52-week low of $7.26 to its 52-week high of $240.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Spruce Biosciences, Inc. (SPRB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.